A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)

In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa

(2019) Katherine Young et al.   BMC MICROBIOLOGY

RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections

(2019) Johann Motsch et al.   CLINICAL INFECTIOUS DISEASES

Epidemiology of carbapenem-resistant Gram-negative infections globally

(2019) Adrian J. Brink   CURRENT OPINION IN INFECTIOUS DISEASES

A translational pharmacokinetic/pharmacodynamic model to characterize bacterial kill in the presence of imipenem-relebactam

(2019) Pratik Bhagunde et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial

(2019) Marin H Kollef et al.   LANCET INFECTIOUS DISEASES

In-vitro activity of imipenem/relebactam and key β-lactam agents against Gram-negative bacilli isolated from lower respiratory tract infection samples of intensive care unit patients – SMART Surveillance United States 2015–2017

(2019) James A. Karlowsky et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Exploring the Pharmacokinetic/Pharmacodynamic Relationship of Relebactam (MK-7655) in Combination with Imipenem in a Hollow-Fiber Infection Model

(2018) Jin Wu et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Intrapulmonary Pharmacokinetics of Relebactam, a Novel β-Lactamase Inhibitor, Dosed in Combination with Imipenem-Cilastatin in Healthy Subjects

(2018) Matthew L. Rizk et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Relebactam Is a Potent Inhibitor of the KPC-2 β-Lactamase and Restores Imipenem Susceptibility in KPC-Producing Enterobacteriaceae

(2018) Krisztina M. Papp-Wallace et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In vitro activity of imipenem/relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme

(2018) James A Karlowsky et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial

(2018) Antoni Torres et al.   LANCET INFECTIOUS DISEASES

Activity of Imipenem-Relebactam against Pseudomonas aeruginosa with Antimicrobial-Resistant Phenotypes from Seven Global Regions—SMART 2015-2016

(2018) James A. Karlowsky et al.   Journal of Global Antimicrobial Resistance

Evidence-Based Study Design for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia

(2018) George H Talbot et al.   JOURNAL OF INFECTIOUS DISEASES

International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia

(2017) Antoni Torres et al.   EUROPEAN RESPIRATORY JOURNAL

Antimicrobial resistance in the next 30 years, humankind, bugs and drugs: a visionary approach

(2017) Matteo Bassetti et al.   INTENSIVE CARE MEDICINE

Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections

(2017) Matthew Sims et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

The respiratory threat posed by multidrug resistant Gram-negative bacteria

(2017) Ana Rodrigo-Troyano et al.   RESPIROLOGY

Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection

(2016) Christopher Lucasti et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society

(2016) Andre C. Kalil et al.   CLINICAL INFECTIOUS DISEASES

High-level resistance to meropenem in clinical isolates of Pseudomonas aeruginosa in the absence of carbapenemases: role of active efflux and porin alterations

(2016) Hussein Chalhoub et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Activity of Meropenem Combined with RPX7009, a Novel β-Lactamase Inhibitor, against Gram-Negative Clinical Isolates in New York City

(2015) Amabel Lapuebla et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012)

(2014) David J. Farrell et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Multistate Point-Prevalence Survey of Health Care–Associated Infections

(2014) Shelley S. Magill et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hospital-Acquired Infections Due to Gram-Negative Bacteria

(2010) Anton Y. Peleg et al.   NEW ENGLAND JOURNAL OF MEDICINE